NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.21 -1.85 (-2.15 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$83.02Now: $84.21▼$87.2550-Day Range$71.37MA: $86.09▼$96.8552-Week Range$62.88Now: $84.21▼$97.10Volume1.78 million shsAverage Volume1.58 million shsMarket Capitalization$15.15 billionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $113.11, BioMarin Pharmaceutical has a potential upside of 34.3% from its current price of $84.21.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesBioMarin Pharmaceutical has received 1,414 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioMarin Pharmaceutical has received 855 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioMarin Pharmaceutical has received 62.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote “Outperform” if you believe BMRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,412,695.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions95.70% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 132.35% in the coming year, from $0.68 to $1.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is -561.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is -561.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.08 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN Previous Symbol CUSIP09061G10 CIK1048477 Webhttp://www.bmrn.com/ Phone415-506-6700Debt Debt-to-Equity Ratio0.16 Current Ratio2.08 Quick Ratio1.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio123.84 P/E GrowthN/A Sales & Book Value Annual Sales$1.70 billion Price / Sales8.89 Cash Flow$0.64 per share Price / Cash Flow131.19 Book Value$17.38 per share Price / Book4.85Profitability EPS (Most Recent Fiscal Year)$0.07 Net Income$-23,850,000.00 Net Margins-1.40% Return on Equity0.81% Return on Assets0.55%Miscellaneous Employees3,001 Outstanding Shares179,926,000Market Cap$15.15 billion Next Earnings Date4/23/2020 (Estimated) OptionableOptionable Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BMRN Rates by TradingView BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMRN shares have decreased by 3.1% and is now trading at $84.21. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for BioMarin Pharmaceutical. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its earnings results on Wednesday, February, 26th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.07. The biotechnology company had revenue of $454.44 million for the quarter, compared to the consensus estimate of $461.88 million. BioMarin Pharmaceutical had a positive return on equity of 0.81% and a negative net margin of 1.40%. View BioMarin Pharmaceutical's earnings history. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.95-2.05 billion, compared to the consensus revenue estimate of $1.95 billion. What price target have analysts set for BMRN? 18 brokers have issued 12-month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $164.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.11 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View analysts' price targets for BioMarin Pharmaceutical. What are Wall Street analysts saying about BioMarin Pharmaceutical stock? Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock: 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs — Vimizim and Kuvan — continue to do well, driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is also progressing well. The company filed regulatory applications for Valrox in late 2019 and targets the same for vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry in the past one year.<" (1/15/2020) 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019) Has BioMarin Pharmaceutical been receiving favorable news coverage? News coverage about BMRN stock has been trending very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBioMarin Pharmaceutical. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 9,938,200 shares, an increase of 9.6% from the February 27th total of 9,070,000 shares. Based on an average daily trading volume, of 1,818,000 shares, the days-to-cover ratio is presently 5.5 days. Approximately 5.6% of the company's stock are short sold. View BioMarin Pharmaceutical's Current Options Chain. Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the following people: Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61) What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fulton Bank N.A. (0.00%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View institutional ownership trends for BioMarin Pharmaceutical. Which major investors are buying BioMarin Pharmaceutical stock? BMRN stock was acquired by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. View insider buying and selling activity for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $84.21. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $15.15 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe. View additional information about BioMarin Pharmaceutical. What is BioMarin Pharmaceutical's official website? The official website for BioMarin Pharmaceutical is http://www.bmrn.com/. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is a Swap?
